Clinical Scorecard: Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma: Integrating Surgical Advances with Molecular Insights

At a Glance

Key Highlights

• CSDH is common in the elderly, with incidence projected to double by 2030.
• MMAE is a minimally invasive treatment targeting arterial supply to neomembranes.
• Mixed results from recent RCTs regarding the efficacy of MMAE.
• MMAE may reduce microbleeding and inflammation, promoting hematoma resorption.
• AI approaches may enhance patient selection and treatment outcomes.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of CSDH is based on clinical presentation and imaging findings.

Management

• Burr-hole craniotomy with drainage is the standard treatment; MMAE may be used as adjunctive or alternative therapy.

Monitoring & Follow-up

• Patients should be monitored for recurrence and treatment response.

Risks

• Recurrence rates of 10%-30% after standard surgical treatment.

Patient & Prescribing Data

Elderly patients with chronic subdural hematoma, often with comorbidities.

MMAE is emerging as a potential adjunctive treatment but requires further study to define its role.

Clinical Best Practices

• Consider MMAE for patients with recurrent CSDH not suitable for repeat surgery.
• Integrate clinical, imaging, and molecular data for personalized treatment approaches.

Related Resources & Content

• Source Article